https://www.marketscreener.com/quote/stock/KEYMED-BIOSCIENCES-INC-124598685/news/License-agreement-with-KYM-Biosciences-for-CMG901-a-Claudin-18-2-antibody-drug-conjugate-completed-43384191/?utm_source=telegram&utm_medium=social&utm_campaign=share